

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Cheatham *et al.* GROUP NUMBER: Not yet assigned
SERIAL NUMBER: Not yet assigned CONFIRMATION NUMBER: Not yet assigned
FILING DATE: Herewith EXAMINER: Not yet assigned
TITLE: METHODS FOR IDENTIFYING THERAPEUTIC TARGETS INVOLVED
IN GLUCOSE AND LIPID METABOLISM

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir

INFORMATION DISCLOSURE STATEMENT

In accordance with the provisions of 37 C.F.R. 1.97 and 1.98, Applicant(s) hereby make of record the patents and publications listed on the accompanying Form PTO-1449, and other information contained herein, for consideration by the Examiner in connection with the examination of the above-identified patent application.

☐ Copies of the patents and publications are enclosed.

OR

☒ In accordance with the U.S. Patent Office's partial waiver of the requirement under 37 C.F.R. 1.98(a)(2)(i), only copies of the foreign patent documents and non-patent publications are enclosed.

In addition, Applicant(s) wish to call to the Examiner's attention the following commonly-owned, co-pending patent application(s) and patents, and Office Action(s) issued therein:

- 1) U.S. Application Serial No. 09/750,401, Attorney Docket No. RBN-001, U.S. Patent No. 6,635,422 B2, issued on 10/21/03;
- 2) U.S. Application Serial No. 10/238,306, Attorney Docket No. RBN-001C1, filed on 09/10/02;
- 2) U.S. Application Serial No. 10/309,788, Attorney Docket No. RBN-001CP, filed on 12/04/02; and
- 3) U.S. Application Serial No. 10/629,453, Attorney Docket No. RBN-001DV, filed on 07/29/03.

REMARKS

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed (CHECK ONE):

- ☒ (1) within three (3) months of the **filing date** of a national application other than a continued prosecution application under 37 C.F.R. 1.53(d), or within three (3) months of the **date of entry of the national stage** as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing of the **first Office Action** on the merits, or before the mailing of a **first Office Action** after the filing of a request for continued examination under 37 C.F.R. 1.114; or
- ☐ (2) after the period defined in (1) but before the mailing date of a **final Action** or a **Notice of Allowance** under 37 C.F.R. 1.311, and
- ☐ the requisite Statement is below, **OR**
- ☐ the requisite fee under 37 C.F.R. 1.17(p), namely **\$180.00**, is included herein, or
- ☐ (3) after the mailing date of a **final Action** or **Notice of Allowance** but before the payment of the **Issue Fee, AND**
- ☐ the requisite Statement is below, **AND**
- ☐ the requisite fee under 37 C.F.R. 1.17(p), namely **\$180.00**, is included herein.

It is respectfully requested that each of the patents and publications listed on the attached Form PTO-1449, and other information contained herein, be made of record in this application.

STATEMENT

As required under 37 C.F.R. 1.97(e), Applicant(s), through the undersigned, hereby state either that [check the appropriate space only if either (2) or (3) is checked above and the Statement is required]:

- ☐ (1) Each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application **not more than three months** prior to the filing of the Information Disclosure Statement; or
- ☐ (2) No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to **any individual**


JC09 Rec'd PCT/PTO 07 OCT 2005

Information Disclosure Statement
Attorney Docket No.: RBN-003
Page 3

designated in 37 C.F.R. 1.56(c) **more than three months** prior to the filing of the
Information Disclosure Statement.

Respectfully submitted,

Date: October 7, 2005
Reg. No. 43,153
Tel. No. (617) 338-2952
Fax No. (617) 338-2880



Diana M. Steel
Attorney for Applicants
Sullivan & Worcester LLP
One Post Office Square
Boston, MA 02109

10/552642

JC09 Rec'd PCT/PTO 07 OCT 2005

EXPRESS MAIL MAILING LABEL NO.: EV593936585US

INFORMATION DISCLOSURE STATEMENT
Form PTO-1449

Complete if Known

Application Serial No.	Not yet assigned
Filing Date	Herewith
First Named Inventor	Cheatham et al.
Examiner Name	Not yet assigned
Group Art Unit	Not yet assigned
Attorney Docket No.	RBN-003

U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Sub Class	Filing Date if Appropriate
	A1	2002/0004211 A1	1/10/02	Keene <i>et al.</i>	435	7.21	
	A2	6,635,422 B2	10/21/03	Keene <i>et al.</i>	435	6	
	A3	5,444,149	08/22/95	Keene et al.	530	300	
	A4	5,525,495	06/11/96	Keene et al.	435	172.3	
	A5	5,541,291	07/30/96	Keene	530	350	
	A6	5,561,222	10/01/96	Keene et al.	530	350	
	A7	5,773,246	06/30/98	Keene et al.	435	69.1	
	A8	5,866,680	02/02/99	Keene et al.	530	324	
	A9	5,882,866	03/16/99	Keene	435	6	
	A10	5,972,620	10/26/99	Keene	435	6	

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country Code	Class	Sub Class	Filing Date	Abstract Only	English Language (Y/N?)

NON PATENT LITERATURE DOCUMENTS

Examiner Initials		Include name of author (in CAPITAL LETTERS), date, title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue numbers, page numbers, publisher, and city where published (when appropriate).
	C1	International Search Report for International Patent Application No. PCT/US2004/010686, dated January 4, 2005, 22 pages.
	C2	Brown <i>et al.</i> , "Microarray Identification of FMFP-Associated Brain mRNAs and Altered mRNA Translational Profiles in Fragile X Syndrome", Nov. 16, 2001, Cell, Vol. 107, pp. 477-487.
	C3	Ceman <i>et al.</i> , "Isolation of an FMRP-Associated Messenger Ribonucleoprotein Particle and Identification of Nucleolin and the Fragile X-Related Proteins as Components of the Complex", Dec. 1999, Molecular and Cellular Biology, pp. 7925-7932.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

INFORMATION DISCLOSURE STATEMENT Form PTO-1449			Complete if Known	
			Application Serial No.	Not yet assigned
			Filing Date	Herewith
			First Named Inventor	Cheatham et al.
			Examiner Name	Not yet assigned
			Group Art Unit	Not yet assigned
			Attorney Docket No.	RBN-003
	C4	Cheatham <i>et al.</i> , "A Ribonomic Analysis of Adipocytes: A Systems Biology Tool", 12/2/02, Online, url: http://www.ribonomics.com/news/presentations/ribonomics_MetabolicDisease2002Poster.pdf >		
	C5	Gavin <i>et al.</i> , "Functional Organization of the Yeast Proteome by Systematic Analysis of Protein Complexes", Jan. 2002, Nature, MacMillan Journals Ltd., London GB, Vol. 415, pp. 141-147.		
	C6	Herold <i>et al.</i> , "Genome-Wide Analysis of Nuclear mRNA Export Pathways in Drosophila", 2003, The EMBO Journal, Vol. 22, No. 10, pp. 2472-2483.		
	C7	Hieronymus <i>et al.</i> , "Genome-Wide Analysis of RNA-Protein Interactions Illustrates Specificity of the mRNA Export Machinery", Feb. 2003, Nature Genetics, Vol. 33, pp. 155-161.		
	C8	Keene, "Ribonucleoprotein Infrastructure Regulating the Flow of Genetic Information Between the Genome and the Proteome", June 19, 2001, PNAS, Vol. 98, No. 13, pp. 7018-7024.		
	C9	Keene <i>et al.</i> , "Eukaryotic mRNPs May Represent Posttranscriptional Operons", June 2002, Molecular Cell, Vol. 9, pp. 1161-1167.		
	C10	Knoch <i>et al.</i> , "Polypyrimidine Tract-Binding Protein Promotes Insulin Secretory Granule Biogenesis", March 2004, Nature Cell Biology, Vol. 6, No. 3, pp. 207-214.		
	C11	Lelivelt <i>et al.</i> , "Yeast Upf Proteins Required for RNA Surveillance Affect Global Expression of the Yeast Transcriptome", Oct. 1999, Molecular and Cellular Biology, Vol. 19, No. 10, pp. 6710-6719.		
	C12	Ohashi <i>et al.</i> , "Identification of mRNA/Protein (mRNP) Complexes Containing Pura, mStaufen, Fragile X Protein, and Myosin Va and their Association with Rough Endoplasmic Reticulum Equipped with a Kinesin Motor", Oct. 2002, The Journal of Biological Chemistry, Vol. 277, No. 40, pp. 37804-37810.		
	C13	Phelps, "Innovative Systems Biology" Nov. 6, 2002, url: http://www.ribonomics.com/news/presentations/ribonomics_RNA_in_Drug_Development .		
	C14	Ribonomics, Inc., "Research & Technology", Mar. 17, 2003, url: http://web.archive.org/web/20030317064208/http://www.ribonomics.com/technology/index.html .		
	C15	Rodgers <i>et al.</i> , "Identifying mRNAs Bound by RNA-Binding Proteins Using Affinity Purification and Differential Display", 2002, Methods, pp. 115-122.		
	C16	Tenenbaum <i>et al.</i> , "Ribonomics: Identifying mRNA Subsets in mRNP Complexes Using Antibodies to RNA-Binding Proteins and Genomic Arrays", Jan. 10, 2002, Methods, pp. 191-198.		
	C17	Tenenbaum <i>et al.</i> , "Identifying mRNA Subsets in Messenger Ribonucleoprotein Complexes by Using cDNA Arrays", Dec. 19, 2000, PNAS, No. 97, No. 26, pp. 14085-14090.		
	C18	Tillmar <i>et al.</i> , "Hypoxia May Increase Rat Insulin mRNA Levels by Promoting Binding of the Polypyrimidine Tract-Binding Protein (PTB) to the Pyrimidine-Rich Insulin mRNA 3'-Untranslated Region", 2002, Molecular Medicine, 8(5), pp. 263-272.		
	C19	Tillmar <i>et al.</i> , "Control of Insulin mRNA Stability in Rat Pancreatic Islets", 2002, The Journal of Biological Chemistry, Vol. 277, No. 2, pp. 1099-1106.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--